Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)
A Randomized, Open Label, Single Center, Dose- and Regimen-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Children and Adults Ages 3 to 64 Years
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
-
San Jose、コスタリカ
- Instituto de Atencion Pediatrica, Avenida 0-2 Calle 22, Paseo Colon del Restaurante La, Bastilla 50 metros Sur, Edificio 5.
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Children, adolescents, and adults 3 to 64 years of age in good health as determined by medical history, physical assessment and clinical judgement of the investigator and without influenza within the past 6 months.
Exclusion Criteria:
- History of serious disease.
- History of serious reaction following administration of vaccine or hypersensitivity to vaccine components.
- Known or suspected impairment/alteration of immune function.
- Receipt or planned receipt of seasonal trivalent influenza vaccine within 1 week before or after each study vaccination.
For additional entry criteria, please refer to protocol.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:2x7.5adj
Two doses of MF59 adjuvanted (adj) A/H1N1
|
MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal
|
実験的:7.5adj_1_8
MF59 adjuvanted (adj) A/H1N1 on days 1 and 8
|
MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal
|
実験的:7.5adj_1_22
MF59 adjuvanted (adj) A/H1N1 on study days 1 and 22
|
MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal
|
実験的:15_1_22
A/H1N1 on study days 1 and 22
|
Unadjuvanted egg-derived A/H1N1 with traces of Thiomersal
|
実験的:2x15_1_22
Two doses of A/H1N1 (one in each arm) on study days 1 and 22
|
Unadjuvanted egg-derived A/H1N1 with traces of Thiomersal
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Percentage of Subjects With Seroconversion and HI Titer ≥1:40 in Children 3 to 17 Years of Age
時間枠:Day 1 to day 387
|
Seroconversion: The percentage of subjects with either a pre-vaccination HI titer < 1:10 and a post-vaccination HI titer >1:40 or a prevaccination HI titer >1:10 and a minimum four-fold rise in post-vaccination HI antibody titer. The analyses were performed on the Per-Protocol Set (PPS). |
Day 1 to day 387
|
Percentage of Subjects With Seroconversion and HI Titer ≥ 1:40 in Adults 18 to 64 Years of Age
時間枠:Day 1 to day 387
|
Seroconversion: The percentage of subjects with either a pre-vaccination HI titer < 1:10 and a post-vaccination HI titer >1:40 or a prevaccination HI titer >1:10 and a minimum four-fold rise in post-vaccination HI antibody titer. Analyses were performed on the Per-Protocol set (PPS). |
Day 1 to day 387
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Age Distribution at Baseline
時間枠:Baseline
|
Baseline
|
|
Percentage of Subjects With Seroconversion and HI Titer ≥1:40, in 3 to <9 Years and 9 to 17 Years
時間枠:Day 1 to day 387
|
Seroconversion: The percentage of subjects with either a pre-vaccination HI titer < 1:10 and a post-vaccination HI titer >1:40 or a prevaccination HI titer >1:10 and a minimum four-fold rise in post-vaccination HI antibody titer. The analyses were performed on the Per-Protocol Set (PPS). |
Day 1 to day 387
|
HI GMRs, in 3 to <9 Years and 9 to 17 Years
時間枠:Day 1 to day 387
|
Geometric Mean Ratios (GMRs) of hemagglutination inhibition (HI) antibody assay (ratio of post-vaccination versus pre-vaccination HI titers). The analyses were performed on the the per-protocol set (PPS). |
Day 1 to day 387
|
HI GMR, in Adults 18 to 64 Years
時間枠:Day 1 to day 387
|
Geometric Mean Ratios (GMRs) of hemagglutination inhibition (HI) antibody assay (ratio of post-vaccination versus pre-vaccination HI titers). The analyses were performed on the Per-Protocol Set (PPS). |
Day 1 to day 387
|
Percentage of Subjects With Seroconversion and HI Titer ≥1:40, in Adults 18 to 64 Years
時間枠:7 days and 21 days after each vaccination
|
Seroconversion: The percentage of subjects with either a pre-vaccination HI titer < 1:10 and a post-vaccination HI titer >1:40 or a prevaccination HI titer >1:10 and a minimum four-fold rise in post-vaccination HI antibody titer. The analyses were performed on the per-protocol set (PPS). |
7 days and 21 days after each vaccination
|
Number of Subjects With at Least One Reactogenicity Sign, in 3 to <9 Years of Age
時間枠:7 days after each vaccination
|
Number of subjects with specified solicited local and systemic reactions in adult subjects (3 to <9 years of age). Postvac: postvaccination; Analges: analgesics; Antipyr: antipyretics. The analyses were performed on the safety set. Note: 1) postvac 1 = after the first vaccination and 2) postvac 2 = after the second vaccination |
7 days after each vaccination
|
Number of Subjects With at Least One Reactogenicity Sign, in 9 to 17 Years of Age
時間枠:7 days after each vaccination
|
Number of subjects with specified solicited local and systemic reactions in adult subjects (9 to 17 years of age). Postvac: postvaccination Analges: analgesics Antipyr: antipyretics The analyses were performed on the safety set. Note: 1) postvac 1 = after the first vaccination and 2) postvac 2 = after the second vaccination. |
7 days after each vaccination
|
Number of Subjects With at Least One Reactogenicity Sign, in 18 to 64 Years of Age
時間枠:7 days after each vaccination
|
Number of subjects with specified solicited local and systemic reactions in adult subjects (18 to 64 years of age). Note: 1) postvac. 1 = after the first vaccination and 2) postvac. 2 = after the second vaccination. The analyses were performed on the safety set. |
7 days after each vaccination
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Novartis Vaccines、Novartis Vaccines
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- V112_04
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
新しい 2009 年インフルエンザ H1N1の臨床試験
-
The University of Hong KongQueen Elizabeth Hospital, Hong Kong; Queen Mary Hospital, Hong Kong; Pamela Youde Nethersole Eastern... と他の協力者完了
-
University of RochesterNational Institutes of Health (NIH)完了
-
David ScheifeleCanadian Institutes of Health Research (CIHR); PHAC/CIHR Influenza Research Network完了
-
Fluart Innovative Vaccine Ltd, Hungary完了インフルエンザ、ヒト | 新しい 2009 年インフルエンザ H1N1ハンガリー
MF59-eH1N1_fの臨床試験
-
SeqirusNovartis Vaccines完了
-
SeqirusDepartment of Health and Human Services募集感染症 | ウイルス病 | 気道感染症 | インフルエンザ、ヒト | 感染ウイルスフィリピン, アメリカ
-
The University of QueenslandSyneos Health; Coalition for Epidemic Preparedness Innovations積極的、募集していない
-
Sanofi Pasteur, a Sanofi Company完了インフルエンザ | 健康ボランティアアメリカ
-
HIV Vaccine Trials NetworkSouth Africa AIDS Vaccine Initiative完了
-
National Institute of Allergy and Infectious Diseases...GlaxoSmithKline; Bill and Melinda Gates Foundation; Medical Research Council; Sanofi Pasteur, a... と他の協力者完了
-
National Institute of Allergy and Infectious Diseases...完了
-
National Institute of Allergy and Infectious Diseases...Novartis Vaccines; HIV Vaccine Trials Network; IPPOX Foundation完了
-
Biomedical Advanced Research and Development AuthorityPPD完了